ResearchMoz

Computational Biology (Pharmacodynamics, Cellular Modeling, Computational Genomics, Proteomics, Pharmacogenomics, Pharmacokinetics, Human Simulation Software, Drug Discovery & Development) Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2012 - 2018

Transparency Market Research
Published Date » 2013-05-07
No. Of Pages » 112

The computational biology market is predicted to have a notable growth owing to its wide use by biotechnology and pharmaceutical companies to reduce the incidences of late stage failures of their drugs and to thereby curb R&D expenditure. Computational biology is also assisting in reducing the extensive use of humans in trials and is therefore useful for pediatric trials, trials on pregnant women and orphan disease research.

This report analyses the global market for computational biology by two main types of studies-cellular modeling and disease modeling. Each of these segments has been further analyzed by various studies with use of simulation, right from drug discovery to drug development. The market has also been bifurcated on the basis of tools which include databases, software and IT infrastructure. The computational biology services market highlights the trend of in-house and contract computational biology. The end users market studies the usage pattern of academic research institutes and commercial industry. All the above mentioned segments are analyzed on the basis of market size in terms of USD million and their forecasts for the period 2012 to 2018 have also been provided. The CAGR (%) for each market segment has been estimated for the forecast period 2012 to 2018, considering 2011 as the base year.
 
Geographically, this market has been divided into four major regions which include North America, Europe, Asia and RoW (Rest of the world). Market sizes, forecasts and % CAGR for each region have been provided. The major drivers, restraints, challenges and growth opportunities and other qualitative dynamics have been considered in the market overview section of this report.

The competitive landscape of this industry has been covered under market share analysis by key players. Our recommendation chapter provides assistance to industry players on ways to enter this market or to establish sustainable competitive advantage.

The global computational biology market is segmented as follows:

Computational Biology Market, By Types
  • Cellular & Biological Simulation
  • Computational Genomics
  • Computational Proteomics
  • Pharmacogenomics
  • Others (Transcriptomics/ Metabolomics)
  • Disease Modeling and Simulation
  • Drug Discovery
  • Target Identification
  • Target Validation
  • Lead Discovery
  • Lead Optimization
  • Drug Development
  • Preclinical
  • Pharmacokinetics
  • Pharmacodynamics
  • Clinical trials
  • Phase I
  • Phase II
  • Phase III
  • Human Body Simulation Software

Computational Biology Market, By Services
  • In-House
  • Contract 

Computational Biology Market, By End Users
  • Academics
  • Industry/ Commercial Players

Computational Biology Market, By Geography
  • North America
  • Europe
  • Asia
  • Rest of the World (RoW)
  • Industry/ Commercial Players
Table of Content

Chapter 1 Introduction
1.1 Report Description
1.2 Market Segmentation
1.3 Scope Of The Report
1.4 Research Methodology
1.4.1 Sources
1.4.1.1 Secondary Research
1.4.1.2 Primary Research
1.4.1.3 Models
1.5 Assumptions

Chapter 2 Executive Summary
2.1 Market Snapshot: Global Computational Biology Market (2011 & 2018)
2.2 Global Computational Biology Market, by Types, 2011 (USD Million)

Chapter 3 Global Computational Biology Market Dynamics
3.1 Market Overview
3.2 Drivers
3.2.1 Failure Of Drug Candidates in Late Stage of Clinical Trials
3.2.1.1 Average Cost to Develop One New Drug (1975 -2011) (USD Million)
3.2.1.2 Trend of Rise in Failure of Phase II Clinical Trials (2006- 2012)
3.2.1.3 Reasons For Failure (%) in Phase II & Phase III
3.2.2 Enhanced Computational Tools
3.2.3 Improved Government Funding &Industrial Support
3.3 Restraints
3.3.1 Lack of Standardization
3.3.2 Non-Verified Predictive Models
3.4 Challenges
3.4.1 Shortage of Skilled Resources
3.4.2 Data Storage
3.5 Opportunities
3.5.1 Cloud Computing
3.5.2 Modelling And Simulations in Paediatrics Drug Development
3.6 Porters Five Forces Analysis
3.6.1 Bargaining Power of Suppliers
3.6.2 Bargaining Power of Buyers
3.6.3 Threat of New Entrants
3.6.4 Threat Of Substitutes
3.6.5 Competitive Rivalry
3.7 Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis: Global Computational Biology Market, by Geography
3.8 End User Analysis
3.8.1 End User Analysis: Global Computational Biology Market, 2011 & 2018 (%)

Chapter 4 Global Computational Biology Market, by Applications
4.1 Introduction
4.1.1 Cellular Modelling and Simulation
4.1.1.1 Computational Genomics
4.1.1.1.1 Global Computational Genomics Market Revenues, 2010 – 2018 (USD Million)
4.1.1.2 Computational Proteomics
4.1.1.2.1 Global Computational Proteomics Market Revenues, 2010 – 2018 (USD Million)
4.1.1.3 Pharmacogenomics
4.1.1.3.1 Global Computational Pharmacogenomics Market Revenues, 2010 – 2018 (USD Million)
4.1.1.4 Others (Metabolomics/ Transcriptomics)
4.1.1.4.1 Global Computational Others (Metabolomics/Transcriptomics) Market Revenue, 2010 – 2018 (USD Million)
4.1.2 Disease Modelling And Simulation Applications / CADD (Computer Aided Drug Design)
4.1.2.1 Drug Discovery
4.1.2.1.1 Global Computational Drug Discovery Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2 Target Identification
4.1.2.1.2.1 Global Computational Target Identification Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.3 Target Validation
4.1.2.1.3.1 Global Computational Target Validation Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.4 Lead Identification/Discovery
4.1.2.1.4.1 Global Computational Lead Identification Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.5 Lead Optimization
4.1.2.1.5.1 Global Computational Lead Optimization Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1 Drug Development
4.1.2.1.1 Preclinical
4.1.2.1.1.1 Global Computational Preclinical Trials Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2 Clinical Trials
4.1.2.1.2.1 Global Computational Clinical Trials Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2.2 Phase I
4.1.2.1.2.3 Global Computational Clinical Trials Phase I Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2.4 Phase II
4.1.2.1.2.5 Global Computational Clinical Trials Phase II Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.2.6 Phase III
4.1.2.1.2.7 Global Computational Clinical Trials Phase III Market Revenues, 2010 – 2018 (USD Million)
4.1.2.1.3 Human Body Simulation Software
4.1.2.1.3.1 Global Computational Human Simulation Software Market Revenues, 2010 – 2018 (USD Million)

Chapter 5 Global Computational Biology Market, by Tools
5.1 Overview
5.2 Database
5.2.1 Global Computational Biology Database Market Revenues, 2010 – 2018 (USD Million)
5.3 IT Infrastructure (Hardware)
5.3.1 Global Computational Biology Hardware Market Revenues, 2010 – 2018 (USD Million)
5.4 Analysis Software & Services
5.4.1 Global Computational Biology Software Market Revenues, 2010 – 2018 (USD Million)

Chapter 6 Global Computational Biology Market, by Services
6.1 Overview
6.2 In-House Computational Biology
6.2.1 Global In-House Computational Biology Market Revenues, 2010 – 2018 (USD Million)
6.3 External/Contract Computational Biology
6.3.1 Global Contract Computational Biology Market Revenues, 2010 – 2018 (USD Million)

Chapter 7 Global Computational Biology Market, by Geography
7.1 Overview
7.2 North America
7.2.1 North America Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.3 Europe
7.3.1 Europe Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.4 Asia
7.4.1 Asia Computational Biology Market Revenues, 2010 – 2018 (USD Million)
7.5 ROW
7.5.1 Row Computational Biology Market Revenues, 2010 – 2018 (USD Million)

Chapter 8 Market Share Analysis
8.1 Market Share by Key Players
8.1.1 Global Computational Biology Market Share Analysis of Key Players, 2011 (%)

Chapter 9 Recommendations
9.1 Success Strategies
9.1.1 Rigorous Research and Development (R&D) Initiatives
9.1.2 Investing in Emerging Economies
9.1.3 Investing in High-End Technologies
9.1.4 Collaborations, Mergers and Acquisitions
9.2 Barriers to be Considered
9.2.1 High Cost of Investment

Chapter 10 Company Profiles
10.1 Accelrys
10.1.1 Company Overview
10.1.2 Financial Overview
10.1.3 Product Portfolio And Services
10.1.4 Business Strategy
10.1.5 Recent Developments
10.2 Certara
10.2.1 Company Profile
10.2.2 Financial Overview
10.2.3 Product Portfolio And Services
10.2.4 Business Strategy
10.2.5 Recent Developments
10.3 Chemical Computing Group Inc.
10.3.1 Company Profile
10.3.2 Financial Overview
10.3.3 Product Portfolio
10.3.4 Business Strategy
10.3.5 Recent Developments
10.4 Compugen, Ltd
10.4.1 Company Profile
10.4.2 Financial Overview
10.4.3 Business Strategy
10.4.4 Recent Developments
10.5 Entelos
10.5.1 Company Profile
10.5.2 Financial Overview
10.5.3 Product Portfolio And Services
10.5.4 Business Strategy
10.5.5 Recent Developments
10.6 Genedata AG
10.6.1 Company Profile
10.6.2 Financial Overview
10.6.3 Product Portfolio And Services
10.6.4 Business Strategy
10.6.5 Recent Developments
10.7 Insilico Biotechnology AG
10.7.1 Company Profile
10.7.2 Financial Overview
10.7.3 Product Portfolio
10.7.4 Business Strategy
10.7.5 Recent Developments
10.8 Leadscope, Inc
10.8.1 Company Profile
10.8.2 FinancialOverview
10.8.3 Product Portfolio
10.8.4 Business Strategy
10.8.5 Recent Developments
10.9 Nimbus Discovery LLC
10.9.1 Company Profile
10.9.2 Financial Overview
10.9.3 Product Portfolio
10.9.4 Business Strategy
10.9.5 Recent Developments
10.10 RhenoviaPharma SAS
10.10.1 Company Profile
10.10.2 Financial Overview
10.10.3 Product Portfolio And Services
10.10.4 Business Startegy
10.10.5 Recent Developments
10.11 Schrodinger
10.11.1 Company Overview
10.11.2 Financial Overview
10.11.3 Product Portfolio And Services
10.11.4 Business Strategy
10.11.5 Recent Developments
10.12 Simulation Plus, Inc.
10.12.1 Company Profile
10.12.2 Financial Overview
10.12.3 Product Portfolio And Services
10.12.4 Business Strategy
10.12.5 Recent Developments

List of Tables

List of Tables

TABLE 1 Global Computational Biology Market: Snapshot (2011 & 2018)
TABLE 2 R&D Function by Expenditure (%)
TABLE 3 Global Computational Biology Market Revenues, by Segments, 2010 – 2018 (USD Million)
TABLE 4 Global Cellular Modeling and Biology Simulation Market Revenues, by Types, 2010 – 2018 (USD Million)
TABLE 5 Global Cellular Modeling and Biology Simulation Market Revenues, by Geography, 2010 – 2018 (USD Million)
TABLE 6 Global Disease Modeling and Simulation Market Revenues, by Types, 2010 - 2018 (USD Million)
TABLE 7 Global Disease Modeling and Simulation Market Revenues, by Geography, 2010 - 2018 (USD Million)
TABLE 8 Global Computational Drug Development Market Revenues, by Types, 2010 - 2018 (USD Million)
TABLE 9 Software Packages for PBPK Modeling
TABLE 10 Global Computational Biology Market Revenues, by Tools, 2010- 2018 (USD Million)
TABLE 11 Global Computational Services Market Revenues, by Services, 2010- 2018 (USD Million)
TABLE 12 Global Computational Biology Market, by Geography, 2010- 2018 (USD Million)

List of Figures

List of Figures

FIG. 1 Global Computational Biology: Market Segmentation
FIG. 2 Global Computational Biology Market, By Types, 2011 (USD Million)
FIG. 3 Average Cost to Develop one New Drug (1975 -2011) (USD Million)
FIG. 4 Trend of Rise in Failure of Phase II Clinical Trials (2006- 2012)
FIG. 5 Reasons for Failure (%) in Phase II & Phase III
FIG. 6 Porter’s Five Forces Analysis for Computational Biology Market
FIG. 7 Market Attractiveness Analysis: Global Computational Biology Market, By Geography
FIG. 8 End User Analysis: Global Computational Biology Market, 2011 & 2018 (%)
FIG. 9 Global Computational Genomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 10 Global Computational Proteomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 11 Global Computational Pharmacogenomics Market Revenues, 2010 – 2018 (USD Million)
FIG. 12 Global Computational Others (Metabolomics/ Transcriptomics) Market Revenue, 2010 – 2018 (USD Million)
FIG. 13 Global Computational Drug Discovery Market Revenues, 2010 – 2018 (USD Million)
FIG. 14 Global Computational Target Identification Market Revenues, 2010 – 2018 (USD Million)
FIG. 15 Global Computational Target Validation Market Revenues, 2010 – 2018 (USD Million)
FIG. 16 Global Computational Lead Identification Market Revenues, 2010 – 2018 (USD Million)
FIG. 17 Global Computational Lead Optimization Market Revenues, 2010 – 2018 (USD Million)
FIG. 18 Global Computational Preclinical Trials Market Revenues, 2010 – 2018 (USD Million)
FIG. 19 Global Computational Clinical Trials Market Revenues, 2010 – 2018 (USD Million)
FIG. 20 Global Computational Clinical Trials Phase I Market Revenues, 2010 – 2018 (USD Million)
FIG. 21 Global Computational Clinical Trials Phase II Market Revenues, 2010 – 2018 (USD Million)
FIG. 22 Global Computational Clinical Trials Phase III Market Revenues, 2010 – 2018 (USD Million)
FIG. 23 Global Computational Human Simulation Software Market Revenues, 2010 – 2012 (USD Million)
FIG. 24 Global Computational Biology Database Market Revenues, 2010 – 2018 (USD Million)
FIG. 25 Global Computational Biology Hardware Market Revenues, 2010 – 2018 (USD Million)
FIG. 26 Global Computational Biology Software Market Revenues, 2010 – 2018 (USD Million)
FIG. 27 Global In-House Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 28 Global Contract Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 29 North America Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 30 Europe Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 31 Asia Computational Biology Market Revenue, 2010 – 2018 (USD Million)
FIG. 32 Row Computational Biology Market Revenues, 2010 – 2018 (USD Million)
FIG. 33 Global Computational Biology Market Share Analysis Of Key Players, 2011 (%)
FIG. 34 Annual Revenues: Accelrys, 2009 - 2011 (USD Million)
FIG. 35 Annual Revenue: Compugen, 2010 – 2012 (USD Million)
FIG. 36 Annual Revenues: Simulation Plus, Inc., 2010 – 2012 (USD Million)

Upcoming Reports:

Carbon Nanomaterials Market - Global Industry Analysis, Size, Share, Growth, Trends, And Forecast, 2012 - 2018
By - Transparency Market Research
The carbon nanomaterials market can be categorized based on product types into – carbon nanotubes, carbon nanofibres, graphene, fullerenes, and POSS (polyhedral oligomeric silsesquioxane). The nanomaterials market has gained importance with technological development and their wide applicability. However, due to the Eurozone crisis, the carbon nanomaterials market experienced slow growth in the past year. Some of the major drivers for the carbon nanomaterials market are their wide application base and easy availability. Also, significant development in the field of...
Pressure Sensitive Adhesive (PSA) Tape Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
Pressure-sensitive adhesive (PSA) tape is a tape having backing material applied with pressure sensitive adhesive material. The adhesive activates quickly when it is kept on substrate and pressure is applied. These types of adhesive do not require any kind of solvent, heat or water to for activation. In order to protect adhesive on tape before end use; sometimes a removable layer is also provided. Though it is industrially termed as PSA tape; it is also known as sticky-tape in domestic use. Pressure sensitive tapes are manufactured industrially by lamination process in which rollers...
Bariatric Surgical Devices Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
By - Transparency Market Research
With a rapid increase in the population suffering from the problem of obesity, the number of bariatric surgeries carried out on a global scale is also increasing continuously, and this increase has further led to a rise in the market for bariatric surgical devices. Bariatric surgery fights obesity by reducing the size of the stomach or through the removal of a portion of the stomach (sleeve gastrectomy or biliopancreatic diversion with a duodenal switch). The global market for bariatric surgical devices is expected to grow at a healthy CAGR during the period from 2013 to 2019 with maximum...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Top End Stereo Systems Maker Harman Targets Chinese Auto Market
Apr 22, 2014  
Harman, the U.S.-based audio company that is best known as the provider of automobile stereos for top-end car models such as Mercedes-Benz, BMW and Ferrari, has said that it has signed agreements with two leading Chinese automakers—Chang’An and Geely. The company, that is associated with premium infotainment systems for leading auto makers, said that these new contracts...
Scientists Identify Cure for Dengue
Apr 18, 2014  
In a breakthrough discovery that can change the way dengue is treated, scientists have identified a drug target for the deadly dengue viruses. This discovery may help pave the way for discovery of vaccines that can cure this condition that affects nearly 390 million people throughout the world each year.  Scientists have used a new technique for this discovery to show that a region...
India is Facing a Cancer Crisis
Apr 15, 2014  
India is currently facing a cancer crisis – reports a recent research carried out at the King’s college London, in collaboration with the Tata Memorial Cancer Centre, Mumbai.  The reasons estimated for this crisis comprise of increasing rates of smoking, unequal access to proper treatment and belated diagnosis.  Every year, India witnesses around one...
Microparticle Tags to Check Counterfeit Goods Invented
Apr 14, 2014  
Researchers from the Massachusetts Institute of Technology have invented a new set of microparticles that can easily be read by smartphones and establish the authenticity of currency, electronic items and luxury goods.  This strategy is among those countless measures taken by big brands and companies to label their legitimate products in order to stop illegal copies of the...
USFDA Approves Lupins Generic Diabetic Drug
Apr 10, 2014  
The United States Food and Drugs Administration (USFDA) has finally approved Lupin Pharmaceuticals Inc (LPI), the American subsidiary of Indian drug manufacturers Lupin Ltd, to sell Pioglitazone Tablets in the U.S market. The approval has been granted first for fiscal 2015.  Pioglitazone is a generic medicine used for managing diabetes and is a version of Actos tablets...